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Abstract
Background: Calgranulin C (S100A12) is an emerging 
marker of inflammation. It is exclusively released by acti-
vated neutrophils which makes this marker potentially 
more specific for inflammatory bowel disease (IBD) com-
pared to established stool markers including calprotectin 
and lactoferrin. We aimed to establish a reference value 
for S100A12 in healthy children and investigated whether 
S100A12 levels can discriminate children with IBD from 
healthy controls.
Methods: In a prospective community-based reference 
interval study we collected 122 stool samples from healthy 
children aged 5–19  years. Additionally, feces samples of 
41 children with suspected IBD (who were later confirmed 
by endoscopy to have IBD) were collected. Levels of 
S100A12 were measured with a sandwich enzyme-linked 
immunosorbent assay (ELISA) (Inflamark®). The limit of 
detection was 0.22 μg/g.
Results: The upper reference limit in healthy children was 
0.75 μg/g (90% confidence interval: 0.30–1.40). Median 
S100A12 levels were significantly higher in patients 
with IBD (8.00 μg/g [interquartile range (IQR) 2.5–11.6] 
compared to healthy controls [0.22 μg/g (IQR < 0.22); 
p < 0.001]). The best cutoff point based on receiver oper-
ating characteristic curve was 0.33 μg/g (sensitivity 93%; 
specificity 97%).
Conclusions: Children and teenagers with newly diag-
nosed IBD have significantly higher S100A12 results 
compared to healthy individuals. We demonstrate that 
fecal S100A12 shows diagnostic promise under ideal test-
ing conditions. Future studies need to address whether 
S100A12 can discriminate children with IBD from non-
organic disease in a prospective cohort with chronic gas-
trointestinal complaints, and how S100A12 performs in 
comparison with established stool markers.
Keywords: adolescent; child; inflammatory bowel disease; 
reference value; S100A12 protein; S100 proteins.
Introduction
Fecal markers are increasingly used as a screening 
test to select children with high suspicion of inflam-
matory bowel disease (IBD) for diagnostic endoscopy 
[1]. Fecal calprotectin (S100A8/A9) is the most studied 
fecal marker for intestinal inflammation. According 
to a recently published meta-analysis (nine studies, 
describing 853 patients), fecal calprotectin has a high 
overall sensitivity of 97% (95% confidence interval [CI] 
92%–99%) and a moderate specificity of 70% (95% CI 
59%–79%) for diagnosing IBD [2]. A calprotectin test 
result in the reference range will thus rule out IBD. This 
can easily be remembered with the mnemonic SnNOut – 
(i.e. when performing a test with high sensitivity [Sn], 
a negative result [N] rules out [Out] the target disease). 
The downside of using calprotectin as screening test 
is that a considerable proportion of the children with 
increased fecal calprotectin values and negative stool 
cultures (22%) do not have IBD, and will be unnecessary 
selected for endoscopy and biopsy [3, 4].
Fecal calgranulin C
Fecal calgranulin C (S100A12) is significantly less inves-
tigated [5] and largely unknown among clinicians as a 
screening test for IBD. Both S100A12 and calprotectin 
are member of the S100 calcium-binding protein family 
and are released from the inflamed mucosa into the gut 
lumen [5]. S100A12 acts independently from calprotectin 
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[6], and is exclusively released by activated neutrophils, 
while calprotectin is released from a multitude of acti-
vated and damaged cells including granulocytes, mono-
cytes, and epithelial cells. As infiltration of neutrophils 
into the intestinal mucosa is one of the most prominent 
histological features in IBD, we think that S100A12 is 
possibly more specific for IBD-associated inflamma-
tion than calprotectin [7, 8]. Both markers are stable for 
3–7 days at room temperature, enabling stool collection 
at home and easy transportation to the hospital labora-
tory [9, 10]. Calprotectin as well as S100A12 concentra-
tions in stools of healthy volunteers show a downward 
trend with age from birth and reach stable values by the 
age of 5 [11–17].
Study aim
In this study we aim to establish a reference value for 
S100A12 in healthy children aged 5 and above. Secondly, 
we investigated if the S100A12  stool test can discrimi-




We collected stool samples of healthy school-aged children and teen-
agers in a prospective community-based reference interval study that 
ran between June 2015 and March 2016. Teenagers were recruited 
from a secondary school in Groningen (The Netherlands), while rep-
resentatives of the younger age group were enrolled via colleagues 
and friends. Participants were eligible for inclusion when they had 
no history of chronic gastro-intestinal disease, and no acute diarrhea 
or use of non-steroidal anti-inflammatory drugs in the week before 
stool collection. Girls were advised not to collect a stool sample dur-
ing their menstrual period.
IBD patients
Children and teenagers with newly diagnosed IBD who had sent in 
a feces sample <6 weeks prior to the confirmatory endoscopy were 
used for comparison. The diagnosis IBD was based on the criteria 
of the European Society for Pediatric Gastroenterology Hepatol-
ogy and Nutrition [18]. The stool samples of these patients were 
stored for the CACATU-study. This trial is registered under identifier 
NCT02197780 in ClinicalTrials.gov, and entails a prospective diag-
nostic study that evaluates the test accuracy of fecal calprotectin 
and S100A12 in children with suspected IBD. The stool samples 
were used with permission of the patients and their legal guardians 
for the current study.
Stool collection and analysis
Participants defecated onto a stool collection sheet (Alere Health 
BV, The Netherlands) held above their own toilet and collected one 
sample with a classical screw top container with spoon, which was 
then sent to the department of Laboratory Medicine in the University 
Medical Centre Groningen in a plastic postage-paid return envelope. 
Transportation time varied between 1 and 7  days, after which the 
samples were stored at −80 °C until analysis. Maximum storage time 
was 6  months. All samples were measured between August 2015 
and June 2016 by one experienced lab technician (LW), who was 
blinded for clinical symptoms of patients. S100A12 analyses were 
performed with a commercially available sandwich enzyme-linked 
immunosorbent assay (ELISA) (Inflamark®, CisBio Bioassays Codo-
let, France) on a Dynex DS2 Automated ELISA System (Alpha Labs, 
Easleigh, UK).
Prior to extraction, fecal samples were thawed at room 
 temperature and 100 mg of the homogenized feces was suspended 
in 1:50 extraction buffer. After vigorous vortex mixing for 30  s and 
incubating on a tube rotator for 25 min, we transferred ~1–2 mL of 
homogenate to an Eppendorf type tube and centrifuged it at 17,100 g 
for 5 min and subsequently diluted the samples 50 times. One hun-
dred microliters aliquots in duplicate of the supernatant were then 
added to the wells coated with anti-S100A12  monoclonal antibody 
of bovine serum albumin. After incubation for 30 min at 600 rpm, 
the plates were washed three times with 300 μL/well of washing 
buffer (3 mL Tween 20 in 1 L distilled water). Then 100 μL of a second 
monoclonal antibody (anti-S100A12 coupled to horse radish-perox-
idase) was added, and the plate was again incubated for 30 min at 
600 rpm and washed. Next 100 μL of tetramethylbenzidine substrate 
was added to initiate the colorimetric reaction. After 10 min the reac-
tion was stopped by adding 100 μL of sulfuric acid. The absorbance 
was read at 450 nm. The ELISA was calibrated with purified human 
S100A12 protein. The calibrator was ready to use after reconstitu-
tion with 0.5 mL distilled water. For each duplicate, the mean opti-
cal density was calculated and a calibration curve was constructed. 
The curve was plotted as a cubic regression with DS-matrix software, 
version 1.23.
Manufacturer’s performance claims are presented in Supple-
mentary Data 1. We verified analytical sensitivity (limit of detection, 
LOD), between-test variation and within-test variation with the auto-
mated DS2 in our laboratory. We calculated the analytical sensitiv-
ity by measuring the extraction fluid 10-times (limit of blank, LOB) 
in one ELISA run and calculated the LOD at 2  standard deviations 
(SDs) of the LOB. We determined the between-run variation using the 
duplicates of the kit control (20 runs) and by selecting three feces 
pools around the same levels as the manufacturers’ claims and deter-
mined the variation between five ELISA runs (each pooled sample 
measured in duplicate). For the within-run variation we used also 
three feces pools (low, intermediate, high). First, we measured one 
extract 20-times in one ELISA plate, and then we repeated the extrac-
tion from each pool 10-times and measured the duplicates on one 
plate.
Data collection and statistics
Demographic information and stool results were recorded electron-
ically using SPSS version 22.0 for Windows (SPSS, Chicago, IL, USA) 
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and are presented with GraphPad Prism version 5 for Windows 
(GraphPad Software, San Diego, CA, USA). Standard descriptive sta-
tistics were used. Not normally distributed variables are presented 
as median and interquartile range (IQR) and tested using the Mann-
Whitney U-test. All tests were two sided and the level of signifi-
cance was set at a p-value <0.05. Reference values were calculated 
by using the simple nonparametric method presented in the Clini-
cal and Laboratory Standards Institute (CLSI) guideline C28-A2 [19]. 
Outliers were detected by performing Dixon’s test and interpreted 
according to Reeds’ criteria: absolute difference between extreme 
observation and the next largest observation (D), divided by the 
range of all observations (R) [20]. If the difference D was equal to 
or greater than one-third of the range of R, the extreme value was 
deleted [21].
The upper reference limit in healthy subjects was defined as the 
97.5th percentile of observations (rank 118.95) [19]. A 90% confidence 
interval (CI) around the upper reference limit was determined using 
the 115 and 121 rank number.
We evaluated the diagnostic accuracy of S100A12 for IBD with 
a receiver operating characteristic (ROC) curve analysis. Sensitivity 
and specificity for the best cut-off point were calculated with their 
95% CIs.
Human patients protection
This study was performed according to the Declaration of Helsinki. 
The Medical Ethics Review Committee of the University Medical 
Centre Groningen confirmed that this study and the earlier men-
tioned CACATU-study were not subject to the Dutch Medical 
Research Involving Human Subjects Act. The data were collected 
and recorded by the investigators in such a manner that subjects 
could not be identified, neither directly nor through identifiers 
linked to the subjects. The legal guardians from all participants, as 
well as the children aged 12 and above, gave informed consent for 
participation.
Results
We tested 122 stool samples from healthy children and 41 
from patients. The baseline characteristics are presented 
in Table 1.
Reference value calgranulin C (healthy 
children)
One outlier was detected according to Dixon and Reed cri-
teria for outliers [21]. This value (5.02 μg/g) was excluded 
from further analysis. The distribution of the remaining 
121 S100A12  measurements is shown in Figure  1. One 
hundred and ten (91%) children presented with a level 
below the LOD. The upper reference limit (97.5 percentile) 
was 0.75 μg/g (90% CI 0.30–1.40).
None of the healthy children had IBD-affected first-
degree relatives. Sixteen participants (13%) reported the 
use of medication that is unlikely to influence the test 
results. Among them were 10 who incidentally used inha-
lation therapy for allergic rhinitis or asthma, while others 
used zopiclon, methylphenidate, incidentally polyethylene 
Table 1: Characteristics of participants.
  Healthy 
(n = 122)
  Newly diagnosed 
with IBD (n = 41)
  p-Value
Gender (boys), n (%)   57 (47%)  21 (51%)  0.59
Age (median, IQR), years   12 (9–14)  14 (12–16)  0.001a
Age groupb       0.04a
5–11 years old, n (%)   53 (44%)  10 (24%) 
12–19 years old, n (%)   68 (56%)  31 (76%) 






















Figure 1: Distribution of fecal calgranulin C (S100A12) test results in 
healthy children and children with newly diagnosed IBD.
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Figure 2: Receiver operating characteristic (ROC) curve of fecal 
calgranulin C (S100A12). 
Area under the curve (AUC) is 0.97 (95% CI 0.93–1.00).
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glycol, oral contraceptives (2×), or growth hormone. A sen-
sitivity analysis comparing the reference values of patient 
with and without medication was not significantly differ-
ent (data not shown). We did not observe any difference 
in mean (SD) S100A12 results when the cohort was divided 
into the age categories 5–11 years and 12–19 years, (respec-
tively, 0.25 ± 0.18 μg/g and 0.24 ± 0.11 μg/g [p = 0.63]). Dif-
ferences in fecal S100A12 levels between boys and girls 
were not found (data not shown).
Diagnostic accuracy calgranulin C
Median fecal S100A12 level in children with IBD was 
8.02 μg/g (IQR 2.3–11.4) and was significantly higher com-
pared to healthy children (Figure 1). Twenty-one children 
were diagnosed with Crohn’s disease, 19  with ulcerative 
colitis and one with IBD-unclassified. Median S100A12 
levels were highest in children with ulcerative colitis 
compared to children with Crohn’s disease (respectively, 
11.0 μg/g [IQR 7.5–28.7] and 6.7 μg/g [IQR 1.3–10.4, p = 0.03]).
The ROC curve depicted in Figure  2 shows that the 
ideal cut-off point to distinguish children with IBD from 
healthy controls leads to a sensitivity of 93% (95% CI 81–
99) and a specificity of 97% (95% CI 92–99). This cut-off 
point corresponds with a S100A12 value of 0.33 μg/g. The 
earlier estimated upper reference limit (0.75 μg/g) leads 
to a sensitivity of 86% (95% CI 71–95) and a specificity of 
98% (95% CI 93–100).
Discussion
Main findings
In this paper we present for the first time the normal value 
of S100A12 using a commercially available testkit. We 
found that the majority of healthy children had S100A12 
levels below the detection limit. We hypothesize that in 
the absence of excessive recruitment and accumulation 
of activated neutrophils in the intestinal lumen, which 
is observed under pathological conditions such as IBD, 
S100A12 can hardly be found in the stool [26]. Secondly, 
we found excellent diagnostic power to distinguish chil-
dren with newly diagnosed IBD from healthy controls.
Comparison with other literature
Diagnostic test development can be divided into four dif-
ferent phases [27]. In Table 2 we summarized the literature 
on fecal S100A12  with respect to these four phases. We 
found one study that described S100A12 levels in a cohort 
of healthy Australian infants and New Zealander children 
[17]. Although this cohort was too small to report reliable 
reference values according to the CLSI guidelines [19], it 
showed a trend towards consistently low levels of S100A12 
in children older than 5 years, with more divergent levels 
of S100A12 below this age, similar to reference values of 
stool calprotectin [13, 16, 17].
The best cutoff point to distinguish healthy children 
from those with newly diagnosed IBD in our study popu-
lation (0.33 μg/g) was substantially lower than previously 
reported cutoff points (0.8 μg/g [25] and 10 μg/g [10]). 
Differences are likely to be explained by differences in 
used assays and selection of patients. At all events, the 
studies agreed on the excellent diagnostic accuracy of the 
S100A12  stool test to distinguish patients with IBD from 
controls [7, 10, 25].
Limitations
The performance of the S100A12 testkit is potentially biased 
due to the case-control design. We compared a preselected 
group of patients with an established diagnosis and healthy 
individuals (rather than testing a group of patients merely 
suspected of IBD). It tells us that the S100A12 test shows 
diagnostic promise under ideal conditions. By establishing 
the pediatric reference range for fecal S100A12 biomarker, 
we have taken an important first step toward harnessing the 
full potential of S100A12 in the pediatric population. Future 
studies need to address whether S100A12 can discriminate 
children with IBD from non-organic disease in a prospec-
tive cohort with chronic gastrointestinal complaints, and 
how S100A12 performs in comparison with established 
stool markers like fecal calprotectin.
Conclusions
The upper reference value of fecal S100A12 in healthy 
children aged 5 and above measured with a commercially 
available assay is 0.75 μg/g. S100A12  shows diagnos-
tic promise under ideal testing conditions with an ideal 
cut-off of 0.33 μg/g.
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